Veridien Announces Bio-Germ Defense Kit, and Anti-Anthrax, Anti-Small Pox Research of its Products' Efficacy; Prestigious Scientific Advisory Board Appointed
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Oct. 24, 2001--VERIDIEN Corporation (OTCBB:VRDE) today announced the introduction of Veridien's Bio-Germ Defense Kit, featuring the company's Environmental Protection Administration (EPA) and Food and Drug Administration (FDA) registered disinfectant and antiseptic products. In concert with the Veridien Bio-Germ Defense Kit, the company is conducting research into the efficacy of the anti-Anthrax and anti-Small Pox qualities of the company's current and prospective new products. Veridien's Bio-Germ Defense Kit is expected to be ready for market in November. Contents of the initial version of the Kit will be announced shortly, and it will continuously be upgraded as research and development of additional products are completed.
For more than a decade, Veridien has been developing disinfectant and antiseptic products to protect individuals from a variety of harmful bacteria and viruses, a fact that has positioned the company to help address the current bio-terrorist threat.
Veridien President and CEO, Sheldon Fenton said, "We are pleased that our company, through years of research and development, is positioned to provide the public with important products at this critical time."
To facilitate these ends, Veridien is pleased to announce the creation of its Scientific Advisory Board, whose prestigious members include:
Jerry A. Moore, Ph.D., served for more than 25 years with the EPA, with 17 of those years in the Pesticide Programs Office in Washington, D.C. Dr. Moore served in the Office of Research and Development in the EPA where he acted as liaison with other federal agencies. Veridien welcomes Dr. Moore's broad expertise in the field of pesticide science and governmental regulation of products used for environmental disinfection.
Brian Chadroff, D.D.S., is a Diplomat of the American Board of Periodontology and Clinical Associate Professor of Post Graduate Periodontology in the Department of Post Graduate Periodontology and Implant Dentistry at the New York University College of Dentistry. Dr. Chadroff has conducted research, published, and lectured nationally and internationally in the field of Bone Grafting and Implant Dentistry and maintains a practice specializing in Periodontics in New York City. Dr. Chadroff's perspective on the use of hard surface disinfection and antimicrobial skin products is a welcome addition to Veridien.
Jerome Kern, Ph.D., is a Microbiologist and Virologist with 40 years of practical experience in Bacteriology, Microbiology and Virology, serving in government, industry, and academia. Dr. Kern has served with the National Institute of Health, National Institute of Allergy and Infectious Diseases, and the National Cancer Institute; Queens Hospital and the University of Hawaii; the Medical University of South Carolina; Litton Bionetics, Inc.; Microbiological Associates, Inc.; Bionetics Research, Inc.; and Veridien Corporation as Laboratory Director from 1996 until his retirement earlier this year. Dr. Kern's continued input into decisions and the future course of Veridien is deeply appreciated.
Sam Garbaway, Ph.D., is a Pharmacist, currently operating a pharmaceutical manufacturing company in Toronto, Canada. Dr. Makerm served with distinction with Boehringer-Mannheim in Germany, where he specialized in the sales and development of clinical chemistry machinery and reagents, with a special focus on human biochemistry test screens. Dr. Makerm has been heavily engaged in the design and production of operating-theater protective clothing. He was an early pioneer in the introduction of a protective shield for use by surgeons during the performance of procedures. Veridien welcomes Dr. Makerm's background and areas of specialty knowledge.
Thomas C. Laipply, M.D., FCAP, FIAP, is a Pathologist and Director of Molecular Tissue Pathology with Nichols Institute-Quest Diagnostics, in San Juan Capistrano, California. Dr. Laipply previously served as Assistant Professor of Pathology at Case Western Reserve University Medical School in Cleveland, Ohio. Dr. Laipply has devoted 20 years to the practice of Pathology and lecturing in selected aspects of Blood Banking, Clinical Cytometry and Cytology, Morphologic Hematology, Immunology and Immunochemistry. For the past decade Dr. Laipply has concentrated his practice in the field of Surgical Pathology. Dr. Laipply has been issued more than 10 U.S. and international patents for anti-infective and invisid fluid applicators. Veridien welcomes Dr. Laipply's clinical expertise and knowledge of the product development process.
About Veridien Corporation
Veridien Corporation is a Health Care Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed PATENTED and UNIQUE PRODUCTS including SURFACE DISINFECTANTS, ANTISEPTIC HAND GELS, a MULTI-USE SKIN AND SURFACE CLEANSER, CONTACT LENS CARE, AND SUN PROTECTANT PRODUCTS. The flagship product Viraguard(R) Hospital Disinfectant/Cleaner and Instrument Presoak is a patented, EPA registered, surface disinfectant, environmentally friendly and nontoxic by OSHA Standard 29 CFR 1910.1200. Viraguard(R) Antiseptic Hand Gel is an FDA drug listed product utilizing a patented Veridien formulation. Veridien's product lines are currently sold internationally through a variety of well-known distributors representing Medical, Dental, Food, Retail and Specialty markets. Veridien's products are also available under private label.
